Achieve Life Sciences, Inc. (ACHV) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low7.1·High7.1
P/FCF
N/A
—
5yr avg: N/A
30Y Low3.6·High88.6
P/B Ratio
↑
9.72
↑+87% vs avg
5yr avg: 5.21
30Y Low0.2·High12.8
ROE
↓
-257.7%
↓+31% vs avg
5yr avg: -374.3%
30Y Low-410%·High33%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low2.6·High8.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACHV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Achieve Life Sciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $253M | $217M | $113M | $82M | $26M | $63M | $22M | $4M | $4M | $6M | $15M |
| Enterprise Value | $248M | $211M | $110M | $83M | $17M | $35M | $-13660837 | $-11931408 | $-5244634 | $1M | $-115300 |
| P/E Ratio → | -3.84 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | 2.97 |
| P/B Ratio | 9.72 | 10.07 | 5.40 | — | 3.13 | 2.25 | 0.59 | 0.24 | 0.27 | 0.82 | 0.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ACHV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | -0.02 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ACHV Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -257.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -418.6% |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | -397.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -257.7% | -257.7% | -409.5% | -869.9% | -233.0% | -101.5% | -53.0% | -96.9% | -107.1% | -78.8% | -71.4% |
| ROA | -135.9% | -135.9% | -137.3% | -120.9% | -109.3% | -75.5% | -47.8% | -81.6% | -87.6% | -56.7% | -47.0% |
| ROIC | — | — | -328.1% | — | — | -3073.7% | -660.4% | -307.7% | -215.2% | -154.0% | -446.1% |
| ROCE | — | — | -256.1% | -786.4% | -158.9% | -82.4% | -53.1% | -97.2% | -108.2% | -49.3% | -74.9% |
ACHV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $21M exceeds total debt of $15M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.69 | 0.69 | 0.48 | — | 1.95 | 0.53 | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.13 | — | -1.03 | -1.00 | -0.96 | -0.90 | -0.60 | -0.67 | -0.80 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -17.92 | -9.55 | -22.81 | — | — | — | — | — | — |
Net cash position: cash ($21M) exceeds total debt ($15M)
ACHV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Achieve Life Sciences, Inc.'s current ratio of 4.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.82x to 4.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.39 | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.75 | 2.93 | 3.22 |
| Quick Ratio | 4.39 | 4.39 | 5.46 | 0.82 | 1.27 | 9.80 | 12.60 | 6.04 | 4.77 | 2.82 | 3.22 |
| Cash Ratio | 4.01 | 4.01 | 5.14 | 0.75 | 1.14 | 9.46 | 12.22 | 5.81 | 4.47 | 2.62 | 3.01 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | 0.18 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 1.27 | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | 36.77 |
ACHV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Achieve Life Sciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $44M | $32M | $20M | $11M | $8M | $3M | $412320 | $175511 | $23972 | $13647 |
Peer Comparison
Compare ACHV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACHVYou | $253M | -3.8 | — | — | — | — | -257.7% | — | — |
 PTGX | $7B | -50.7 | — | 112.8 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 ATAI | $1B | -4.5 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 GFAI | $11M | -0.9 | — | — | 17.2% | -18.5% | -20.5% | -41.6% | — |
 OWLT | $3B | -2.3 | — | — | 50.6% | -7.9% | -588.0% | -48.1% | — |
 CHRS | $212M | 1.2 | — | — | -37.3% | -429.5% | 275.4% | — | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 CLOV | $1B | -15.8 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 MNKD | $1B | 178.0 | 27.5 | 80.1 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 63.9% | -5.5% | -33.8% | -11.0% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See ACHV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACHV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACHV vs PTGX
Side-by-side business, growth, and profitability comparison vs Protagonist Therapeutics, Inc..
Start ComparisonACHV — Frequently Asked Questions
Quick answers to the most common questions about buying ACHV stock.
What is Achieve Life Sciences, Inc.'s P/E ratio?
Achieve Life Sciences, Inc.'s current P/E ratio is -3.8x. The historical average is 94.4x.
What is Achieve Life Sciences, Inc.'s ROE?
Achieve Life Sciences, Inc.'s return on equity (ROE) is -257.7%. The historical average is -75.0%.
Is ACHV stock overvalued?
Based on historical data, Achieve Life Sciences, Inc. is trading at a P/E of -3.8x. Compare with industry peers and growth rates for a complete picture.